Turning the Thymus into an Engine of Immune Tolerance in T1D and Beyond

Episode Summary

Executive Summary: Jason Cole explains how ZagBio aims to prevent type 1 diabetes by using thymus-targeting antibodies to generate long-lived, antigen-specific T regulatory cells that restore immune tolerance. He contrasts this approach with existing diabetes management and broader autoimmune strategies, highlights promising preclinical data, and outlines an initial clinical focus on adults with stage 3 disease before potentially moving earlier in the disease course and into other autoimmune indications.

Main Topics: The thymus as a tolerance engine (Priority: 5/5): Cole describes the thymus as the immune system’s training ground, where T cells learn to avoid attacking self and where T regulatory cells are generated. ZagBio’s strategy is to leverage this natural biology therapeutically by introducing disease-relevant antigens to induce durable immune tolerance. Type 1 diabetes biology and unmet need (Priority: 5/5): The discussion distinguishes type 1 diabetes as an autoimmune destruction of pancreatic beta cells from type 2 diabetes, which is driven by metabolic and genetic factors. Current management relies on insulin delivery technology rather than disease modification, leaving a major unmet need for prevention and durable control. ZagBio’s thymic training platform and ZAG 101 (Priority: 5/5): ZAG 101 is presented as a bifunctional antibody that homes to the thymus and delivers a type 1 diabetes antigen to train antigen-specific T regs in vivo. The goal is to create long-lived immune protection that can home to the pancreas and suppress autoimmune attack. Positioning within the immune tolerance landscape (Priority: 4/5): Cole places ZagBio among emerging tolerance approaches, including peripheral tolerance via nanoparticles and ex vivo cell therapy approaches. He argues ZagBio is differentiated because it creates native thymic T regs in vivo, which may be more durable and less likely to revert. Clinical strategy, biomarkers, and development path (Priority: 4/5): The initial clinical plan is to start in adults with stage 3 type 1 diabetes for safety and proof-of-mechanism, using C-peptide and T-cell biomarkers to assess preservation of beta-cell function and immune effects. The company hopes to move earlier to stage 2 and stage 1 disease if early data support the approach. Broader autoimmune pipeline potential (Priority: 4/5): Beyond type 1 diabetes, ZagBio sees potential in other antigen-driven autoimmune diseases such as ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and synovial diseases by swapping the target antigen while using the same thymus-homing platform. Leadership, investor support, and patient perspective (Priority: 3/5): Cole shares his personal experience living with type 1 diabetes and frames the role as mission-driven but data-focused. He also describes building ZagBio in a capital-efficient way and notes support from strategic investors such as AbbVie, Regeneron, and Sanofi.

Key Arguments: Type 1 diabetes is fundamentally an autoimmune disease, so the most meaningful therapy would prevent beta-cell destruction rather than only replace insulin. The thymus can be repurposed to generate antigen-specific, long-lived T regulatory cells, offering a potentially durable tolerance mechanism. ZagBio’s in vivo approach may be more durable than ex vivo Treg engineering because native thymic Tregs can persist for decades and are less likely to revert. Bystander suppression may allow a single antigen-targeted therapy to have broader immunologic effects across multiple relevant diabetes antigens. Starting in adults with stage 3 disease provides a safer proof-of-mechanism path, while earlier-stage intervention could ultimately prevent progression altogether. C-peptide is the key biomarker for disease modification because preserving it indicates retained beta-cell function and insulin production. The same thymus-homing platform could be redeployed for other autoimmune diseases simply by changing the antigen payload. Cole argues that patient passion and objective data discipline are both necessary for deciding which programs to advance or stop.

Data Points: Americans with type 1 diabetes: 1.6 million - Cole cites the U.S. patient population to illustrate disease burden. Global type 1 diabetes population: 9 million - Cole cites the worldwide prevalence of type 1 diabetes. Company funding round: $80 million - ZagBio recently raised this amount with strategic investor participation. CEO tenure at ZagBio: about 9 months - Cole says he was not very familiar with the thymus until joining the company roughly nine months earlier. Age at diagnosis: late 40s - Cole describes his own late-life diagnosis with type 1 diabetes. Family history duration: 40 years - Cole says his father lived with type 1 diabetes for four decades before dying from complications. Adulthood diagnosis share: just under 50% - Cole notes that nearly half of type 1 diabetes cases are diagnosed in adulthood. Clinical starting population: adults with stage 3 disease - Initial trial plans are to enroll newly diagnosed adults who still retain beta cells. Key biomarker: C-peptide - Used to track preservation of beta-cell function and insulin production in the first-in-human study.

Pivotal Quotes: "the thymus is a fascinating organ ... it essentially trains your T cells to be your immune system" — Jason Cole: Explaining the biological basis for ZagBio’s thymus-targeting strategy. "What ZAG is doing, I think, is a little more elegant" — Jason Cole: Contrasting ZagBio’s in vivo thymic Treg induction with other tolerance approaches. "this time it's personal" — Jason Cole: Describing how his own type 1 diabetes diagnosis influenced his decision to lead ZagBio.

Implications: If ZagBio’s approach works, it could shift autoimmune therapy from chronic management to durable immune reset, first in type 1 diabetes and potentially in other antigen-defined autoimmune diseases.